Gurpreet Singh Jawanda, FNP

Gurpreet Jawanda practices at Southern California Permanente Medical Group in Pasadena, California.

Gurpreet Jawanda's NPI, 1407500739, was assigned on February 6, 2022. Gurpreet Jawanda holds California license 95019194.

Gurpreet Jawanda's primary practice is Southern California Permanente Medical Group, at 393 E Walnut St, Pasadena, CA 91101 in Los Angeles County. The practice phone is (800) 353-5400.

Gurpreet Jawanda's primary practice is Southern California Permanente Medical Group in Pasadena, California. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Gurpreet Jawanda to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Gurpreet Jawanda practices, 2 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Gurpreet Jawanda's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Gurpreet Jawanda is licensed in California.

Dmand AI lists insomnia and tobacco use among the conditions Gurpreet Jawanda treats.

CMS data shows 186 Medicare services from Gurpreet Jawanda across 3 procedure codes in 2024, all of them office visits, for 162 Medicare patients. Medicare paid $7,878 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 162 Medicare patients who saw Gurpreet Jawanda in 2024. The largest group is 65 to 74, with 88 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 46% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Gurpreet Jawanda's median patient age at 47, with 79% women.

In 2024, Gurpreet Jawanda wrote 1,072 Medicare Part D claims for 279 patients. 89% of them were for generic drugs. CMS names the drug for 862 of them, across 24 drugs with 11 or more claims each, at $70,380 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Gurpreet Jawanda for performance year 2024, reported as part of a group. Gurpreet Jawanda accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 9 general payments to Gurpreet Jawanda from 7 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Medtronic, Inc. paid the most, $45.